You are here: Industry Insights > Tivozanib

News List

FDA Approves Tivozanib for Relapsed/Refractory Advanced Renal Cell Carcinoma americanpharmaceuticalreview
March 18, 2021
The U.S. Food and Drug Administration (FDA) approved tivozanib (Fotivda, AVEO Pharmaceuticals), a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
AVEO Oncology announces FDA acceptance for filing of an NDA for Tivozanib as treatment of relapsed o pharmaceutical-business-review
June 04, 2020
AVEO Oncology announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib ...
Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma drugs
December 27, 2019
Among patients with metastatic renal cell carcinoma, progression-free survival was longer in those receiving tivozanib versus sorafenib as third- or fourth-line therapy ...
Kyowa Kirin buys back Tivozanib rights from AVEO oncology biospectrumasia
August 04, 2019
Kyowa Kirin will reobtain the non-oncology rights of tivozanib in AVEO territories excluding the rights which are currently sublicensed to EUSA Pharma
AVEO Announces Clinical and Regulatory Updates for Tivozanib americanpharmaceuticalreview
February 13, 2017
AVEO Oncology has announced clinical and regulatory updates for its lead drug candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).